However, the presence of SOX2, together with increasing knowledge regarding the production of iPS cells using penetrating peptides (CPPs) [51], and the factors recently reported as modulating the biology of these SOX2+ cells [52]–[54], might help in the future to either modulate their behaviour in vivo or expand the SOX2+ progenitor cells in vitro before transplantation into chronic sclerotic MS plaques. This evidence concerns the gene SOX2 and myeloid sarcoma.